NSE · SUDARSHAN
Sudarshan Pharma Ind Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹166 Cr with net profit ₹6 Cr — a 3.65% net margin, versus 4.77% the period before.
Shareholding
As of 2026-09-30
- Promoter57.81%
- Public20.24%
- FII21.95%
1,250 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.31× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 1.11 percentage points to 57.81% in the latest disclosure.
Peer comparison
Trading · ranked #58 of 689 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,37,004 Cr | 130.91 | 3.56 | 3.93% | 6.78% |
| Avenue Supermarts Limited | ₹2,08,739 Cr | 66.97 | 8 | 11.94% | 4.2% |
| Trent Ltd. | ₹1,50,404 Cr | 82.26 | 21.6 | 24.62% | 8.64% |
| FSN E-Commerce Ventures Ltd. | ₹97,227 Cr | 364.95 | 67.54 | 13.87% | 2.41% |
| Aditya Infotech Limited | ₹48,661 Cr | 101.96 | 14.42 | 19.61% | 9.77% |
| Aegis Logistics Limited | ₹42,124 Cr | 33.66 | 6.33 | 20.01% | 14.99% |
| Vishal Mega Mart Limited | ₹41,222 Cr | 45.83 | 5.22 | 11.37% | 6.45% |
| Premier Energies Limited | ₹39,131 Cr | 23.5 | 9.04 | 35.05% | 19.67% |
| Redington Limited | ₹27,995 Cr | 15.56 | 2.76 | 14.67% | 1.33% |
| Honasa Consumer Limited | ₹14,733 Cr | 58.39 | 10.43 | 14.16% | 9.75% |
| Sudarshan Pharma Ind Ltd.(this company) | ₹882 Cr | 35.01 | 5.28 | 15.03% | 3.43% |
AI analysis
AI-generated · google/gemini-2.5-flashSudarshan Pharma Industries Ltd., with a market capitalization of Rs 967 Cr, reported an EPS of 0.97 and a book value of 6.44. The company's PE ratio is 41.44. Its 52-week high is 42.79 and its 52-week low is 18.5.
Positives
- +The profit margin is high at 331.55%.
- +Return on Equity (ROE) is 15.03%.
- +Return on Capital Employed (ROCE) is 12.76%.
Negatives
- −The debt-to-equity ratio is 1.13.
- −The company is currently under ESM surveillance.
- −Promoter holding decreased from 57.3898% in Q1 2025 (June 30 2025) to 57.3898% in Q4 2026 (March 31 2026).
- −No dividend yield was reported.
Financial Performance
For the fiscal year ending March 2025, Sudarshan Pharma Industries Ltd. recorded a net profit of Rs 15.9552 Cr on revenue of Rs 507.5668 Cr, with an EPS of 0.66. In the quarter ending March 2026, the company's net profit was Rs 10.73 Cr on revenue of Rs 220.92 Cr. The company's profit margin stood at 331.55% as per the latest available data.
Profitability & Returns
The company's Return on Equity (ROE) is 15.03%, while its Return on Capital Employed (ROCE) is 12.76%. The latest reported profit margin is 331.55%.
Balance Sheet
Sudarshan Pharma Industries Ltd. has a debt-to-equity ratio of 1.13. No dividend yield information is available.
Ownership & Pledges
There are no reported promoter share pledges.
Regulatory & Surveillance
The company is currently under ESM surveillance, specifically in ESM 1, indicating enhanced surveillance measures.
Data as of — price: 2026-10-28 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.